Angiogenic factors in atrial fibrillation: A possible role in thrombogenesis?

References

• Lip G. Y. H., Hart R. G., Conway D. S. Antithrombotic therapy for atrial fibrillation. BMJ 2002; 325: 1022–5
   PubMedGoogle Scholar
• Lip G. Y. H. Does atrial fibrillation confer a hypercoagulable state?. Lancet 1995; 346: 1313–4
   PubMed Web of Science ®Google Scholar
• Lip G. Y. H., Lowe G. D., Rumley A., Dunn F. G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73: 527–33
   PubMedGoogle Scholar
• Lip G. Y. H. The prothrombotic state in atrial fibrillation: the atrium, the endothelium and tissue factor?. Thromb Res 2003; 111: 133–5
   PubMed Web of Science ®Google Scholar
• Li‐Saw‐Hee F. L., Blann A. D., Gurney D., Lip G. Y. H. Plasma von Willebrand factor, fibrinogen and soluble P‐selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001; 22: 1741–7
   PubMed Web of Science ®Google Scholar
• Mondillo S., Sabatini L., Agricola E., Ammaturo T., Guerrini F., Barbati R., et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 2000; 75: 227–32
   PubMed Web of Science ®Google Scholar
• Feng D., D'Agostino R. B., Silbershatz H., Lipinska I., Massaro J., Levy D., et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol 2001; 87: 168–71
   PubMed Web of Science ®Google Scholar
• Conway D. S., Pearce L. A., Chin B. S., Hart R. G., Lip G. Y. H. Plasma von Willebrand factor and soluble p‐selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106: 1962–7
   PubMed Web of Science ®Google Scholar
• Conway D. S. G., Pearce L. A., Chin B. S. P., Hart R. G., Lip G. Y. H. Prognostic value of plasma von Willebrand factor and soluble P‐selectin as indices of endothelial damage and platelet activation in 994 patients with nonvavular atrial fibrillation. Circulation 2003; 107: 3141–5
   PubMed Web of Science ®Google Scholar
• Takahashi N., Ishibashi Y., Shimada T., Sakane T., Ohata S., Sugamori T., et al. Atrial fibrillation impairs endothelial function of forearm vessels in humans. J Card Fail 2001; 7: 45–54
   PubMed Web of Science ®Google Scholar
• Minamino T., Kitakaze M., Sato H., Asanuma H., Funaya H., Koretsune Y., Hori M. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol 1997; 17: 3191–5
   PubMed Web of Science ®Google Scholar
• Roldan V., Marin F., Blann A. D., Garcia A., Marco P., Sogorb F., et al. Interleukin‐6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24: 1373–80
   PubMed Web of Science ®Google Scholar
• Felmeden D. C., Blann A. D., Lip G. Y. H. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003; 24: 586–603
   PubMed Web of Science ®Google Scholar
• Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–5
   PubMed Web of Science ®Google Scholar
• Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P. C., et al. Vascular permeability factor: a tumor‐derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535–45
   PubMed Web of Science ®Google Scholar
• Blum S., Issbruker I., Willuweit A., Hehlgans S., Lucerna M., Mechtcheriakova D., et al. An inhibitory role of the phosphatidylinositol 3‐kinase‐signaling pathway in vascular endothelial growth factor‐induced tissue factor expression. J Biol Chem 2001; 276: 33428–34
   PubMedGoogle Scholar
• Morrissey J. H. Tissue factor: an enzyme cofactor and true receptor. Thromb Haemost 2001; 86: 66–74
   PubMed Web of Science ®Google Scholar
• Seko Y., Nishimura H., Takahashi N., Ashida T., Nagai R. Serum levels of vascular endothelial growth factor and transforming growth factor‐β1 in patients with patients with atrial fibrillation undergoing defibrillation therapy. Jpn Heart J 2000; 41: 27–32
   Google Scholar
• Chung N. A., Belgore F., Li‐Saw‐Hee F. L., Blann A. D., Lip G. Y. H. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?. Stroke 2002; 33: 2187–91
   PubMed Web of Science ®Google Scholar
• Toi M., Matsumoto T., Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2: 667–73
   PubMed Web of Science ®Google Scholar
• Etoh T., Inoue H., Tanaka S., Barnard G. F., Kitano S., Mori M. Angiopoietin‐2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001; 61: 2145–53
   PubMed Web of Science ®Google Scholar
• Huang Y. Q., Li J. J., Hu L., Lee M., Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001; 86: 1094–8
   PubMed Web of Science ®Google Scholar
• Sfiligoi C., de Luca A., Cascone I., Sorbello V., Fuso L., Ponzone R., et al. Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003; 103: 466–74
   PubMed Web of Science ®Google Scholar
• Oh H., Takagi H., Suzuma K., Otani A., Matsumara M., Honda Y. Hypoxia and Vascular endothelial growthb factor selectively upregulate Angiopoietin‐2 in bovine microvascular endothelial cells. J Biol Chem 1999; 274: 15732–9
   PubMed Web of Science ®Google Scholar
• Chong A. Y., Caine G. J., Freestone B., Blann A. D., Lip G. Y. H. Plasma angiopoietin‐1, angiopoietin‐2, and angiopoietin receptor tie‐2 levels in congestive heart failure. J Am Coll Cardiol 2004; 43: 423–8
   PubMed Web of Science ®Google Scholar
• Boyaci A., Topaloglu S., Yilmaz S., Yanik O., Ozdemir O., Demir A. D., et al. Regional left atrial coagulation and fibrinolytic activities in patients with mitral stenosis. Jpn Heart J 2004; 45: 779–88
   PubMedGoogle Scholar
• Kumagai K., Fukuchi M., Ohta J., Baba S., Oda K., Akimoto H., et al. Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling. Circ J 2004; 68: 321–7
   Google Scholar
• Fukuchi M., Watanabe J., Kumagai K., Katori Y., Baba S., Fukuda K., et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001; 37: 1436–42
   PubMed Web of Science ®Google Scholar
• Gimbrone M. A Jr. Vascular endothelium, haemodynamic forces and atherogenesis. Am J Pathol 1999; 155: 1–5
   PubMed Web of Science ®Google Scholar
• Topper J. N., Cai J., Falb D., Gimbrone M. A Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclo‐oxygenase‐2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up‐regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996; 93: 10417–22
   PubMed Web of Science ®Google Scholar
• Seko Y., Seko Y., Takahashi N., Shibuya M., Yazaki Y. Pulsatile stretch stimulates vascular endothelial growth factor (VEGF) secretion by cultured rat cardiac myocytes. Biochem Biophys Res Commun 1999; 254: 462–5
   PubMed Web of Science ®Google Scholar
• Chang H., Shyu K. G., Wang B. W., Kuan P. Regulation of hypoxia‐inducible factor 1α by cyclical mechanical stretch in rat vascular smooth muscle cells. Clin Sci 2003; 105: 447–56
   Google Scholar
• Fielder U., Scharpfenecker M., Koidl S., Hegen A., Grunow V., Schmidt J. M., et al. The Tie‐2 ligand Angiopoietin‐2 is stored in and rapidly released upon stimulation from endothelial cell Weibel Palade bodies. Blood 2004; 103: 1450–6
   Google Scholar
• Davis S., Aldrich T. H., Jones P. F., Acheson A., Compton D. L., Jain V., et al. Isolation of Angiopoietin‐1, a ligand for the Tie2 receptor by secretion‐trap expression cloning. Cell 1996; 87: 11161–9
   Google Scholar
• Maisonpierre P. C., Suri C., Jones P. F., Bartunkova S., Wiegand S. J., Radziejewski C., et al. Angiopoietin‐2, a natural antagonist for Tie2 that interrupts in‐vivo angiogenesis. Science 1997; 277: 55–60
   PubMed Web of Science ®Google Scholar
• Makin A. J., Chung N. A. Y., Silverman S. L., Lip G. Y. H. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis?. Clin Sci 2003; 104: 397–404
   Google Scholar
• Papatropoulos A., Garcia‐Cardena G., Madri J. A., Sessa W. C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131–9
   Google Scholar
• Nishino M., Hoshida S., Tanouchi J., Ito T., Kato J., Iwai K., et al. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000; 85: 1451–4
   PubMedGoogle Scholar
• Pedram A., Razandi M., Levin E. R. Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology 2001; 142: 1578–86
   PubMed Web of Science ®Google Scholar
• Beck H., Acker T., Weissner C., Allegrini P. R., Plate K. H. Expression of angiopoietin‐1, angiopoietin‐2 and Tie receptors after middle cerebral artery occlusion in the rat. Am J Pathol 2000; 157: 1473–83
   PubMed Web of Science ®Google Scholar
• Issa R., Krupinski J., Bujny T., Kumar S., Kaluza J., Kumar P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 1999; 79: 417–25
   PubMed Web of Science ®Google Scholar